Appropriateness of ciprofloxacin dosing based on a population pharmacokinetic model

Alexandra Perreiter, David E. Nix, Kathryn R Matthias

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Over the past two decades, the minimum inhibitory concentrations (MICs) of ciprofloxacin have been steadily increasing for gram-negative bacteria. One major reason cited for this "MIC creep" is underdosing of ciprofloxacin due to a lack of understanding of its pharmacodynamic properties. The primary objective of this study was to evaluate the frequency of underdosing of ciprofloxacin in a tertiary acute care medical center based on a population pharmacokinetic model. Secondary objectives included evaluation of appropriateness of dosing based on renal function and approved product labeling.Methods: Seventy-six patients were included in this single-center, retrospective study. Data collection included demographic, laboratory, and microbiology data along with details on antibiotic administration. Patient-specific predicted 24-hour area under the curve/MIC (AUC 24/MIC) values were estimated using a population pharmacokinetic model with a goal predicted AUC24/MIC of at least 100 and a preferred target value of 250.Results: Only 8% of the subjects obtained a predicted AUC24/MIC higher than 250, while 34% of the subjects achieved a predicted AUC24/MIC of 100 or less. The majority of patients (79%) received a total daily intravenous-equivalent dose of 800 mg, whereas only 8% of subjects received an initial total daily intravenous-equivalent dose of 1,200 mg, which is the recommended dose for most severe infections. Overall 26% of subjects were prescribed an appropriate initial dose for their estimated renal function based on infection type and severity.Conclusion: Ciprofloxacin for acute infection treatment was frequently underdosed based on US Food and Drug Administration-approved labeling and estimated predicted AUC24/MIC at a tertiary acute care medical center.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalHospital Pharmacy
Volume45
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Pharmacokinetics
Microbial Sensitivity Tests
Ciprofloxacin
Health care
Labeling
Population
Pharmacodynamics
Microbiology
Tertiary Healthcare
Area Under Curve
Bacteria
Creep
Infection
Product Labeling
Anti-Bacterial Agents
Kidney
United States Food and Drug Administration
Gram-Negative Bacteria
Retrospective Studies
Demography

Keywords

  • Antimicrobial stewardship
  • Ciprofloxacin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Pharmacy

Cite this

Appropriateness of ciprofloxacin dosing based on a population pharmacokinetic model. / Perreiter, Alexandra; Nix, David E.; Matthias, Kathryn R.

In: Hospital Pharmacy, Vol. 45, No. 3, 2010, p. 237-243.

Research output: Contribution to journalArticle

@article{f8fd12c33f2d4d489fb71b4567cd1561,
title = "Appropriateness of ciprofloxacin dosing based on a population pharmacokinetic model",
abstract = "Purpose: Over the past two decades, the minimum inhibitory concentrations (MICs) of ciprofloxacin have been steadily increasing for gram-negative bacteria. One major reason cited for this {"}MIC creep{"} is underdosing of ciprofloxacin due to a lack of understanding of its pharmacodynamic properties. The primary objective of this study was to evaluate the frequency of underdosing of ciprofloxacin in a tertiary acute care medical center based on a population pharmacokinetic model. Secondary objectives included evaluation of appropriateness of dosing based on renal function and approved product labeling.Methods: Seventy-six patients were included in this single-center, retrospective study. Data collection included demographic, laboratory, and microbiology data along with details on antibiotic administration. Patient-specific predicted 24-hour area under the curve/MIC (AUC 24/MIC) values were estimated using a population pharmacokinetic model with a goal predicted AUC24/MIC of at least 100 and a preferred target value of 250.Results: Only 8{\%} of the subjects obtained a predicted AUC24/MIC higher than 250, while 34{\%} of the subjects achieved a predicted AUC24/MIC of 100 or less. The majority of patients (79{\%}) received a total daily intravenous-equivalent dose of 800 mg, whereas only 8{\%} of subjects received an initial total daily intravenous-equivalent dose of 1,200 mg, which is the recommended dose for most severe infections. Overall 26{\%} of subjects were prescribed an appropriate initial dose for their estimated renal function based on infection type and severity.Conclusion: Ciprofloxacin for acute infection treatment was frequently underdosed based on US Food and Drug Administration-approved labeling and estimated predicted AUC24/MIC at a tertiary acute care medical center.",
keywords = "Antimicrobial stewardship, Ciprofloxacin, Pharmacokinetics",
author = "Alexandra Perreiter and Nix, {David E.} and Matthias, {Kathryn R}",
year = "2010",
doi = "10.1310/hpj4503-237",
language = "English (US)",
volume = "45",
pages = "237--243",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "3",

}

TY - JOUR

T1 - Appropriateness of ciprofloxacin dosing based on a population pharmacokinetic model

AU - Perreiter, Alexandra

AU - Nix, David E.

AU - Matthias, Kathryn R

PY - 2010

Y1 - 2010

N2 - Purpose: Over the past two decades, the minimum inhibitory concentrations (MICs) of ciprofloxacin have been steadily increasing for gram-negative bacteria. One major reason cited for this "MIC creep" is underdosing of ciprofloxacin due to a lack of understanding of its pharmacodynamic properties. The primary objective of this study was to evaluate the frequency of underdosing of ciprofloxacin in a tertiary acute care medical center based on a population pharmacokinetic model. Secondary objectives included evaluation of appropriateness of dosing based on renal function and approved product labeling.Methods: Seventy-six patients were included in this single-center, retrospective study. Data collection included demographic, laboratory, and microbiology data along with details on antibiotic administration. Patient-specific predicted 24-hour area under the curve/MIC (AUC 24/MIC) values were estimated using a population pharmacokinetic model with a goal predicted AUC24/MIC of at least 100 and a preferred target value of 250.Results: Only 8% of the subjects obtained a predicted AUC24/MIC higher than 250, while 34% of the subjects achieved a predicted AUC24/MIC of 100 or less. The majority of patients (79%) received a total daily intravenous-equivalent dose of 800 mg, whereas only 8% of subjects received an initial total daily intravenous-equivalent dose of 1,200 mg, which is the recommended dose for most severe infections. Overall 26% of subjects were prescribed an appropriate initial dose for their estimated renal function based on infection type and severity.Conclusion: Ciprofloxacin for acute infection treatment was frequently underdosed based on US Food and Drug Administration-approved labeling and estimated predicted AUC24/MIC at a tertiary acute care medical center.

AB - Purpose: Over the past two decades, the minimum inhibitory concentrations (MICs) of ciprofloxacin have been steadily increasing for gram-negative bacteria. One major reason cited for this "MIC creep" is underdosing of ciprofloxacin due to a lack of understanding of its pharmacodynamic properties. The primary objective of this study was to evaluate the frequency of underdosing of ciprofloxacin in a tertiary acute care medical center based on a population pharmacokinetic model. Secondary objectives included evaluation of appropriateness of dosing based on renal function and approved product labeling.Methods: Seventy-six patients were included in this single-center, retrospective study. Data collection included demographic, laboratory, and microbiology data along with details on antibiotic administration. Patient-specific predicted 24-hour area under the curve/MIC (AUC 24/MIC) values were estimated using a population pharmacokinetic model with a goal predicted AUC24/MIC of at least 100 and a preferred target value of 250.Results: Only 8% of the subjects obtained a predicted AUC24/MIC higher than 250, while 34% of the subjects achieved a predicted AUC24/MIC of 100 or less. The majority of patients (79%) received a total daily intravenous-equivalent dose of 800 mg, whereas only 8% of subjects received an initial total daily intravenous-equivalent dose of 1,200 mg, which is the recommended dose for most severe infections. Overall 26% of subjects were prescribed an appropriate initial dose for their estimated renal function based on infection type and severity.Conclusion: Ciprofloxacin for acute infection treatment was frequently underdosed based on US Food and Drug Administration-approved labeling and estimated predicted AUC24/MIC at a tertiary acute care medical center.

KW - Antimicrobial stewardship

KW - Ciprofloxacin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=77953019106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953019106&partnerID=8YFLogxK

U2 - 10.1310/hpj4503-237

DO - 10.1310/hpj4503-237

M3 - Article

AN - SCOPUS:77953019106

VL - 45

SP - 237

EP - 243

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 3

ER -